CoChat
Cited by 209

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease: Reinstatement of cognitive function by sildenafil

Open access
Cuadrado-Tejedor, M, Hervias, I, Ricobaraza, A, Puerta, E, Pérez-Roldán, JM, García-Barroso, C, Franco, R, Aguirre, N, García-Osta, A · 2011 · British Journal of Pharmacology

Abstract

BACKGROUND AND PURPOSE: Inhibitors of phosphodiesterase 5 (PDE5) affect signalling pathways by elevating cGMP, which is a second messenger involved in processes of neuroplasticity. In the present study, the effects of the PDE5 inhibitor, sildenafil, on the pathological features of Alzheimer's disease and on memory-related behaviour were investigated. EXPERIMENTAL APPROACH: Sildenafil was administered to the Tg2576 transgenic mouse model of Alzheimer's disease and to age-matched negative littermates (controls). Memory function was analysed using the Morris water maze test and fear conditioning tasks. Biochemical analyses were performed in brain lysates from animals treated with saline or with sildenafil. KEY RESULTS: Treatment of aged Tg2576 animals with sildenafil completely reversed their cognitive impairment. Such changes were accompanied in the hippocampus by a reduction of tau hyperphosphorylation and a decrease in the activity of glycogen synthase kinase 3β (GSK3β) and of cyclin-dependent kinase 5 (CDK5) (p25/p35 ratio). Moreover, sildenafil also increased levels of brain-derived neurotrophic factor (BDNF) and the activity-regulated cytoskeletal-associated protein (Arc) in the hippocampus without any detectable modification of brain amyloid burden. CONCLUSIONS AND IMPLICATIONS: Sildenafil improved cognitive functions in Tg2576 mice and the effect was not related to changes in the amyloid burden. These data further strengthen the potential of sildenafil as a therapeutic agent for Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01517.x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Ahlijanian, 2000, Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5, Proc Natl Acad Sci USA, 97, 2910, 10.1073/pnas.040577797 · DOI · Paper page
  2. Alvarez, 2001, A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons, Exp Cell Res, 264, 266, 10.1006/excr.2001.5152 · DOI
  3. Avila, 2007, GSK-3 inhibitors for Alzheimer's disease, Expert Rev Neurother, 7, 1527, 10.1586/14737175.7.11.1527 · DOI
  4. Bernabeu, 1997, Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats, Proc Natl Acad Sci USA, 94, 7041, 10.1073/pnas.94.13.7041 · DOI · Paper page
  5. Dash, 1990, Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation, Nature, 345, 718, 10.1038/345718a0 · DOI · Paper page
  6. Devan, 2004, Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats, Pharmacol Biochem Behav, 79, 691, 10.1016/j.pbb.2004.09.019 · DOI
  7. Devan, 2006, Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition, Psychopharmacology (Berl), 183, 439, 10.1007/s00213-005-0232-z · DOI
  8. Devan, 2007, Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester, Eur J Pharmacol, 563, 134, 10.1016/j.ejphar.2007.02.008 · DOI
  9. Dickey, 2003, Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice, J Neurosci, 23, 5219, 10.1523/JNEUROSCI.23-12-05219.2003 · DOI · Paper page
  10. Dickey, 2004, Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice, J Neurochem, 88, 434, 10.1111/j.1471-4159.2004.02185.x · DOI
  11. Elyaman, 2002, In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation, Eur J Neurosci, 15, 651, 10.1046/j.1460-9568.2002.01899.x · DOI
  12. Guzowski, 2002, Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches, Hippocampus, 12, 86, 10.1002/hipo.10010 · DOI · Paper page
  13. Guzowski, 1997, Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training, Proc Natl Acad Sci USA, 94, 2693, 10.1073/pnas.94.6.2693 · DOI · Paper page
  14. Guzowski, 1999, Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles, Nat Neurosci, 2, 1120, 10.1038/16046 · DOI · Paper page
  15. Haghikia, 2007, Long-term potentiation in the visual cortex requires both nitric oxide receptor guanylyl cyclases, J Neurosci, 27, 818, 10.1523/JNEUROSCI.4706-06.2007 · DOI
  16. Han, 2007, Neuronal competition and selection during memory formation, Science, 316, 457, 10.1126/science.1139438 · DOI · Paper page
  17. Hartell, 1996, Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression, J Neurosci, 16, 2881, 10.1523/JNEUROSCI.16-09-02881.1996 · DOI
  18. Hsiao, 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
  19. Huang, 2006, Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease, Curr Drug Targets, 7, 1389, 10.2174/1389450110607011389 · DOI
  20. Impey, 1996, Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus, Neuron, 16, 973, 10.1016/S0896-6273(00)80120-8 · DOI · Paper page
  21. Johnson-Wood, 1997, Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease, Proc Natl Acad Sci USA, 94, 1550, 10.1073/pnas.94.4.1550 · DOI
  22. Josselyn, 2001, Long-term memory is facilitated by cAMP response element-binding protein overexpression in the amygdala, J Neurosci, 21, 2404, 10.1523/JNEUROSCI.21-07-02404.2001 · DOI · Paper page
  23. Koh, 2007, Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS, Exp Neurol, 205, 336, 10.1016/j.expneurol.2007.03.004 · DOI
  24. Lau, 2002, Cdk5 as a drug target for the treatment of Alzheimer's disease, J Mol Neurosci, 19, 267, 10.1385/JMN:19:3:267 · DOI
  25. Lee, 2000, Neurotoxicity induces cleavage of p35 to p25 by calpain, Nature, 405, 360, 10.1038/35012636 · DOI · Paper page
  26. Lee, 2004, Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein, J Neurosci Res, 76, 572, 10.1002/jnr.20127 · DOI
  27. Liu, 2002, Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta, FEBS Lett, 530, 209, 10.1016/S0014-5793(02)03487-7 · DOI · Paper page
  28. Lopes, 2007, Amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies, Cell Mol Neurobiol, 27, 943, 10.1007/s10571-007-9224-3 · DOI
  29. Loughney, 1998, Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase, Gene, 216, 139, 10.1016/S0378-1119(98)00303-5 · DOI · Paper page
  30. Lu, 1999, Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus, J Neurosci, 19, 10250, 10.1523/JNEUROSCI.19-23-10250.1999 · DOI · Paper page
  31. Lyford, 1995, Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites, Neuron, 14, 433, 10.1016/0896-6273(95)90299-6 · DOI · Paper page
  32. Malm, 2007, Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden, J Neurosci, 27, 3712, 10.1523/JNEUROSCI.0059-07.2007 · DOI
  33. Otth, 2002, AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576, J Alzheimers Dis, 4, 417, 10.3233/JAD-2002-4508 · DOI
  34. Patil, 2006, Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats, Pharmacol Rep, 58, 373
  35. Patrick, 1999, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature, 402, 615, 10.1038/45159 · DOI · Paper page
  36. Paul, 2008, Signaling through cGMP-dependent protein kinase I in the amygdala is critical for auditory-cued fear memory and long-term potentiation, J Neurosci, 28, 14202, 10.1523/JNEUROSCI.2216-08.2008 · DOI
  37. Price, 1999, Tangles and plaques in nondemented aging and ‘preclinical’ Alzheimer's disease, Ann Neurol, 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
  38. Prickaerts, 2002a, cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation, Eur J Pharmacol, 436, 83, 10.1016/S0014-2999(01)01614-4 · DOI
  39. Prickaerts, 2002b, Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat, Neuroscience, 113, 351, 10.1016/S0306-4522(02)00199-9 · DOI · Paper page
  40. Puerta, 2009, Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat, J Neurochem, 108, 755, 10.1111/j.1471-4159.2008.05825.x · DOI
  41. Puerta, 2010, Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF, Neurobiol Dis, 38, 237, 10.1016/j.nbd.2010.01.013 · DOI
  42. Puzzo, 2009, Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model, J Neurosci, 29, 8075, 10.1523/JNEUROSCI.0864-09.2009 · DOI · Paper page
  43. Reed, 2010, Effect size of reference memory deficits in the Morris water maze in Tg2576 mice, Behav Brain Res, 212, 115, 10.1016/j.bbr.2010.03.037 · DOI
  44. Reyes-Irisarri, 2005, Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain, Neuroscience, 132, 1173, 10.1016/j.neuroscience.2005.01.050 · DOI
  45. Ricobaraza, 2009, Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model, Neuropsychopharmacology, 34, 1721, 10.1038/npp.2008.229 · DOI · Paper page
  46. Rutten, 2005, The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices, Behav Brain Res, 164, 11, 10.1016/j.bbr.2005.04.021 · DOI
  47. Rutten, 2008, Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques, Psychopharmacology, 196, 643, 10.1007/s00213-007-0999-1 · DOI
  48. Sasaki, 2002, Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites, Virchows Arch, 441, 358, 10.1007/s00428-002-0643-8 · DOI
  49. Son, 1998, The specific role of cGMP in hippocampal LTP, Learn Mem, 5, 231, 10.1101/lm.5.3.231 · DOI
  50. Stanciu, 2001, Phosphorylated cAMP response element binding protein in the mouse brain after fear conditioning: relationship to Fos production, Brain Res Mol Brain Res, 94, 15, 10.1016/S0169-328X(01)00174-7 · DOI · Paper page
  51. Steward, 2001, Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation, Neuron, 30, 227, 10.1016/S0896-6273(01)00275-6 · DOI · Paper page
  52. Thind, 2007, Pathological correlates of cognitive decline in Alzheimer's disease, Panminerva Med, 49, 191
  53. Tomidokoro, 2001, Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice, Neurosci Lett, 299, 169, 10.1016/S0304-3940(00)01767-5 · DOI
  54. Tsai, 2004, Cdk5, a therapeutic target for Alzheimer disease?, Biochim Biophys Acta, 1697, 137, 10.1016/j.bbapap.2003.11.019 · DOI
  55. Tully, 2003, Targeting the CREB pathway for memory enhancers, Nat Rev Drug Discov, 2, 267, 10.1038/nrd1061 · DOI · Paper page
  56. Twomey, 2006, Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate, FEBS Lett, 580, 4015, 10.1016/j.febslet.2006.06.035 · DOI
  57. Vitolo, 2002, Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling, Proc Natl Acad Sci USA, 99, 13217, 10.1073/pnas.172504199 · DOI · Paper page
  58. Westerman, 2002, The relationship between Aβeta and memory in the Tg2576 mouse model of Alzheimer's disease, J Neurosci, 1, 1858, 10.1523/JNEUROSCI.22-05-01858.2002 · DOI · Paper page

Cited by

See all 209

Metadata

Authors
Cuadrado-Tejedor, M., Hervias, I., Ricobaraza, A., Puerta, E., Pérez-Roldán, J., García-Barroso, C., Franco, R., Aguirre, N., & García-Osta, A.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2011-11-21
Volume
164
Issue
8
Pages
2029-2041
ISSN
0007-1188 (ISSN-L)
OpenAlex
W2124627119
Cited by
209
References
19
FWCI
8.28
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1380 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.